/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. BioTech Nation ... with Dr. Moira Gunn
  2. Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics
Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

BioTech Nation ... with Dr. Moira Gunn · Sep 29, 2026

Reimagining chemotherapy: Intensity Therapeutics injects drugs directly into tumors, personalizing dosage and activating the immune system.

Modern Chemotherapy Dosing Relies on an Archaic 19th-Century Metric Unrelated to Tumor Size

Current chemotherapy doses are calculated using patient height and weight, a method from the 1800s. This metric has zero correlation with tumor size or burden, leading to suboptimal treatment efficacy for many cancer patients.

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics thumbnail

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

BioTech Nation ... with Dr. Moira Gunn·2 months ago

Intensity Therapeutics' Direct Injection Turns a Patient's Own Tumor into a Personalized Cancer Vaccine

By killing cancer cells directly within the tumor, the treatment exposes the patient's unique, mutated cancer antigens to their immune system. This effectively trains immune cells to recognize and attack similar cancer cells throughout the body, creating a highly personalized, in-situ vaccine.

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics thumbnail

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

BioTech Nation ... with Dr. Moira Gunn·2 months ago

Intensity Therapeutics Bypasses Drug Resistance by Using Physical Diffusion Instead of Biological Receptors

The company's drug formulation doesn't rely on specific cell receptors, which cancers often mutate to evade treatment. Instead, it uses a physical diffusion process to permeate any cancer cell, rendering receptor-based mutations irrelevant and overcoming a major hurdle in cancer therapy.

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics thumbnail

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

BioTech Nation ... with Dr. Moira Gunn·2 months ago

Intensity's Delivery Platform Enables Use of Potent Drugs Previously Deemed Too Toxic for Systemic Therapy

The company's technology is a delivery system. By containing potent compounds within the tumor via direct injection, it can make previously shelved drugs—those too toxic for systemic use—viable therapies, creating a new pipeline of cancer treatments.

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics thumbnail

Reengineering Chemotherapy for Solid Tumors...Lew Bender, Founder, President & CEO, Intensity Therapeutics

BioTech Nation ... with Dr. Moira Gunn·2 months ago